Jennifer Tidey
Associate Professor of Psychiatry & Human Behavior Research:
Bio Med Alcohol & Addiction
Phone: +1 401 863 6418
Jennifer_Tidey@Brown.EDU
There is a very high prevalence of cigarette smoking (>70%) among people with serious mental illness. Dr. Tidey's research focuses on biological, environmental and social factors that influence cigarette smoking in people with schizophrenia. She also studies medications and behavioral treatments for tobacco and alcohol dependence in adults and adolescents without serious mental illness.
Biography
Brief Bio
Dr. Tidey is an Associate Professor of Psychiatry and Human Behavior (Research), a faculty member in the Center for Alcohol and Addiction Studies and the Director of the Center's Addictive Behaviors Research Laboratory. She received her PhD in Experimental Psychology, specializing in psychopharmacology, from Tufts University in 1995. She was a postdoctoral fellow in the Center's NIAAA-funded training program in 1999-2000. Her primary research interests include human behavioral pharmacology laboratory studies on drug interactions and potential pharmacotherapies for addiction, contingency management interventions to reduce drug use, and biological and environmental factors underlying drug use in people with major mental illness.
Dr. Tidey is the PI of two NIDA-funded projects that examine biological and behavioral mechanisms underlying cigarette smoking in people with schizophrenia. In addition, she is co-investigator on 8 NIH-funded grants examining medications or behavioral treatments for tobacco or alcohol dependence. Dr. Tidey's recent publications focus on biological and behavioral mechanisms underlying tobacco and alcohol dependence in adults and adolescents.
Interests
Jennifer Tidey is the Principal Investigator (PI) on two National Institute on Drug Abuse (NIDA)-funded projects that focus on biological and behavioral mechanisms underlying cigarette smoking in people with schizophrenia. In addition, she is a Co-Investigator on eight NIH-funded grants that examine the effects of pharmacological and/or behavioral interventions for tobacco and alcohol dependence in adults and adolescents.
Degrees
PHD
Awards
Early Career Investigator Award, College on Problems of Drug Dependence, 1997
Senator Proctor Research Award, American Lung Association of Vermont, 1998
Director's Travel Award, National Institute on Drug Abuse (NIDA), 1999
Research Excellence Award, Center for Alcohol and Addiction Studies, Brown University, 2000, 2002, 2007
Memorial Travel Fellow, American College of Neuropsychopharmacology (ACNP), 2002
Service Award, Society for Research on Nicotine and Tobacco (SRNT), 2006
Affiliations
College on Problems of Drug Dependence (CPDD), 2002 – present
--CPDD Travel Awards and Mentoring Committee, 2002 – 2007
--CPDD Program Committee 2007 - present
Society for Research on Nicotine and Tobacco (SRNT), 2000 – present
--SRNT Conference Program Co-Chair, 2005-2006
Behavioral Pharmacology Society, 1992 – present
International Study Group Investigating Drugs as Reinforcers, 1996 – present
Research Society on Alcoholism, 1999 – present
Teaching
T-32 NIAAA/NIDA Postdoctoral Fellowship Seminars, Brown University CAAS "How to give an effective presentation" (2003), "Responding to pink sheets" (2001-2005), "Neurobiology Seminar Series: Behavioral pharmacology of opiates, cocaine, nicotine, and everything else" (2002-2005), "Neurobiology Seminar Series: Pharmacotherapy for dependence on nicotine, cocaine or opiates" (2003-2005), "Contingency management interventions" (2002-2004), "Studying smokers with schizophrenia in the human behavioral pharmacology laboratory" (2003), "Tips for IRB success" (2004-2005), Internal reviewer of post-doctoral fellow grant applications (2003-2005)
Lecture given within course entitled "Alcohol Use and Misuse" (BC168.13, Dept of Public Health): "Neurobiology and psychopharmacology of stimulants, nicotine and cross-addictions." (2003-2006).
Funded Research
CURRENT FUNDING
1.Smoking Abstinence and Lapse Effects in Smokers with Schizophrenia and Controls (PI: Tidey), National Institute on Drug Abuse, June 2009 – May 2011, Project direct costs: $275,000; Project total costs: $444,750
2. Biological and Behavioral Mechanisms of Smoking in Schizophrenia (PI: Tidey), National Institute on Drug Abuse, June 2006 – March 2010, Project direct costs: $725,000; Project total costs: $1,148,677
3. Biobehavioral Effects of Topiramate on Cannabis-Related Outcomes in Adolescents (PI: Miranda), National Institute on Drug Abuse, June 2009 – May 2011, Project direct costs: $691,094; Project total costs: $1,117,259
4.Biobehavioral Mechanisms of Topiramate and Drinking (PI: Monti), National Institute on Alcohol Abuse and Alcoholism, January 2006 - December 2010, Project direct costs: $2,043,580; Project total costs: $3,076,890
5. Motivation and Skills for Detained Teen Smokers (PI: Stein), National Institute on Drug Abuse, September 2007 – June 2012, Project direct costs: $179,765; Project total costs: $285,827
6. Mechanisms Linking Alcohol Use and Smoking Relapse Risk (PI: Kahler), National Institute on Drug Abuse, April 2008 – December 2012, Project direct costs: $1,221,901; Project total costs: $1,941,922
7. Varenicline and Motivational Advice for Smokers with SUD (PI: Rohsenow), National Institute on Drug Abuse, June 2008 – March 2013, Project direct costs: $2,241,138; Project total costs: $3,506,761
8. Contingent Vouchers for Smoking in Substance Abusers as Adjunct to Nicotine Patch (PI: Rohsenow), National Institute on Drug Abuse, July 2008 – May 2013, Project direct costs: $2,252,702; Project total costs: $3,511,976
9. Contingency Management for Alcohol Abuse Using Transdermal Alcohol Detection (PI: Barnett), National Institute on Alcohol Abuse and Alcoholism, September 2008 – August 2010, Project direct costs: $275,000; Project total costs: $437,250
10. Enhancing Alcoholism Pharmacotherapy Research via Behavioral Economics (PI: MacKillop), National Institute on Alcohol Abuse and Alcoholism, September 2008 – August 2013, Project direct costs: $691,210; Project total costs: $746,507
PAST FUNDING
1. Smoking versus Alternative Reinforcers in Adolescents (PI: Colby), National Institute on Drug Abuse, Sept 2003 - July 2009, Project direct costs: $1,250,000; Project total costs: $1,931,258
2. Ondansetron and Naltrexone: Cue Reactivity and Drinking (PI: Rohsenow), National Institute on Alcohol Abuse and Alcoholism, June 2003 - May 2009, Project direct costs: $925,000; Project total costs: $1,438,450
3. Incentives plus Bupropion for Smoking in Schizophrenics (PI: Tidey), National Institute on Drug Abuse, Sept 2003 - March 2009, Project direct costs: $837,135; Project total costs: $1,291,759
4. Elucidating Mechanisms of Pharmacotherapy for Alcoholism (PI: Miranda), National Institute on Alcohol Abuse and Alcoholism, April 2004 - March 2009, Project direct costs: $637,595; Project total costs: $688,602
5. Understanding Craving for Alcohol via Behavioral Economics (PI: MacKillop), Alcoholic Beverage Medical Research Foundation (ABMRF), July 2007 – June 2009, Project direct costs: $86,932; Project total costs: $99,972
6. Contingency Management and MET for Adolescent Smoking (PI: Monti), National Institute on Drug Abuse, July 2002 - July 2008, Project direct costs: $2,259,891; Project total costs: $3,538,230
7. Baclofen Effects on Smoking Urge, Withdrawal and Preference (PI: Rohsenow), Department of Veterans Affairs Merit Review, Oct 2005 - June 2008, Project direct costs: $450,000; Project total costs: 450,000
8. Transdermal Nicotine and Bupropion-SR in Schizophrenics (PI: Tidey), National Institute on Drug Abuse, Sept 2001 - June 2006, Direct costs: $600,000; Total costs: $929,574
9. Motivating Substance Abusers to Quit Smoking (PI: Rohsenow), National Institute on Drug Abuse, April 2001 - Jan 2006, Project direct costs: $2,026,780; Project total costs: $3,157,705
10. Naltrexone, Craving and Drinking: Ecological Assessment (PI: Monti), National Institute on Alcohol Abuse and Alcoholism, April 2000 - April 2005; Project direct costs: $1,812,009; Project total costs: $2,654,442
11. Effects of Olanzapine on Cigarette Cue Reactivity and Reinforcement (Rohsenow), Department of Veterans Affairs Merit Review, Oct 2001 - Sept 2004, Project direct costs: $417,400; Project total costs: $417,400
12. Does Transdermal Nicotine Help Schizophrenics Reduce Smoking? (PI: Tidey), American Lung Association of Vermont, July 1998 – July 1999, Direct costs: $5,000; Total costs: $5,000
13. Alcohol Intervention/Treatment Outcome Research Training Grant (PI: Longabaugh), National Institute on Alcohol Abuse and Alcoholism, October 1999 – October 2000
14. Training in Behavioral Pharmacology of Human Drug Dependence Training Grant (Bickel), National Institute on Drug Abuse, July 1996 - June 1999
